Search results
B.Riley lifts Vaxart shares target on BARDA award By Investing.com
Investing.com· 4 days agoThe award, which could total up to $453 million, is for conducting a Phase IIb study involving...
Hawaii Health Department warns of high COVID activity
Honolulu Star-Advertiser· 4 days agoThe Hawaii Department of Health issued a Wednesday news release reminding the public to be vigilant...
Past COVID infections may help protect against certain colds. Could it lead to better vaccines?
The Virginian-Pilot· 5 days agoA new study suggests previous COVID-19 infections lower the risk of getting colds caused by milder...
SF wastewater levels show spike in COVID-19
The San Francisco Examiner· 7 hours agoAmanda Bidwell of Stanford University’s WastewaterSCAN project said the current levels of COVID-19 in wastewater samples collected from sites across the...
FDA Tells Vaccine Makers to Target New COVID Variant for Fall
WFMZ Eastern Pennsylvania and Western New Jersey· 4 days agoCOVID vaccine makers will be advised to update their shots to target the KP.2 variant, an offshoot...
Past COVID infections may help protect against certain colds
WJZY via Yahoo News· 5 days agoA new study suggests previous COVID-19 infections lower the risk of getting colds caused by milder...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-...
Digital Journal· 5 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-< ...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-...
Morningstar· 5 days ago(NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary ...
Novavax seeks FDA nod for updated COVID-19 vaccine By Investing.com
Investing.com· 3 days agoFood and Drug Administration (FDA) for its updated JN.1 COVID-19 vaccine, NVX-CoV2705, for...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-...
The Kansas City Star· 5 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-< ...